Meaningful Relief for People Living with Osteoarthritis
Relevium Medical's novel targeted prodrug therapeutic RM-010 is designed to ease the burden of pain and restore mobility
THE PROBLEM
Osteoarthritis: More Than Joint Degeneration
Globally, more than 500 million people live with osteoarthritis. This progressive disease touches the entire joint – cartilage, bone, and the surrounding tissues all change over time, contributing to pain, swelling, stiffness, and reduced mobility. The knee is among the most commonly affected joints.
Yet structural changes alone don’t explain why the pain feels the way it does, or why it lingers. Beneath the surface, the synovium becomes inflamed, and the sensory nerve fibers within the joint grow increasingly hyperexcitable, sustaining pain. For people living with osteoarthritis, this persistent pain makes everyday life harder – walking, exercising, working, sleeping, simply getting around – and with it, their overall well-being.
IMPACT
The Failures of Current Treatments
For a condition this common, the treatment options remain woefully limited. Patients are left cycling through inadequate treatments, without ever targeting the mechanism sustaining the pain. This persistent treatment gap leaves millions with unmanaged pain and a worsening quality of life.
Where Current Treatments Fall Short
Oral pain medicines
NSAIDs & opioids
Only gives short-term pain relief.
Significant systemic side effects with prolonged use.
Addiction potential with opioids.
Corticosteroid injections
Provide relief for only a few weeks.
Repeated use limited due to concerns around cartilage health.
Viscosupplementation
Limited relief, designed primarily to improve joint lubrication.
Variable clinical benefit.
The opportunity
What if pain relief could be delivered directly where it is needed - and designed to last?
Relevium’s RM-010
OUR SOLUTION
RM-010 is designed for exactly this gap – a treatment that precisely targets the nerve fibers driving chronic osteoarthritis pain and is delivered directly into the joint. By engaging TRPV1 through controlled, prodrug-based release, RM-010 offers meaningful, lasting relief without the tolerability trade-offs.
Platform Potential: The First Application of a Broader Platform
PLATFORM POTENTIAL
RM-010 represents the first application of Relevium Medical's prodrug technology to osteoarthritis.
The underlying platform is modular, allowing formulations to be tailored to different tissues, therapeutic targets, and other hyperexcitability indications.
This creates the potential to extend the platform beyond the knee and to develop new approaches for other conditions where localised, sustained symptom management could address significant unmet needs.